Neurocrine Biosciences (NBIX) to Release Earnings on Monday

Neurocrine Biosciences (NASDAQ:NBIX) will likely be announcing its Q1 2025 earnings results after the market closes on Monday, May 5th. Analysts expect the company to announce earnings of $0.70 per share and revenue of $587.06 million for the quarter.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Trading Up 2.9 %

NASDAQ NBIX opened at $109.68 on Friday. The company has a market cap of $10.85 billion, a PE ratio of 33.34, a PEG ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $157.98. The stock’s 50-day moving average price is $106.19 and its two-hundred day moving average price is $121.84.

Neurocrine Biosciences declared that its board has approved a share repurchase program on Friday, February 21st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 4.2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. HC Wainwright lowered their price target on Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating on the stock in a research report on Tuesday, April 22nd. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. UBS Group decreased their price target on Neurocrine Biosciences from $154.00 to $137.00 and set a “buy” rating on the stock in a research report on Friday, April 4th. Royal Bank of Canada raised shares of Neurocrine Biosciences from a “sector perform” rating to an “outperform” rating and dropped their target price for the stock from $138.00 to $137.00 in a research note on Monday, April 14th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a “hold” rating and a $138.00 target price for the company. Three investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $160.90.

Insiders Place Their Bets

In related news, Director Kevin Charles Gorman sold 5,844 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the sale, the director now owns 521,618 shares in the company, valued at approximately $60,867,604.42. This represents a 1.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Matt Abernethy sold 2,558 shares of Neurocrine Biosciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $116.86, for a total transaction of $298,927.88. Following the transaction, the chief financial officer now directly owns 34,775 shares of the company’s stock, valued at approximately $4,063,806.50. This represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,530 shares of company stock worth $1,722,989 over the last three months. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.